Search research articles
Contact Us
Filters
Showing results (41-50 of 78) with videos related to
Page
of 8
Sort By:
Scientific Reports
|
May 25, 2021
Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p
Roberto H Barbier, Edel M McCrea, Kristi Y Lee, et al.
The Oncologist
|
August 1, 2021
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single-Dose Administration Under Fasting Conditions in Prostate Cancer
Lisa M Cordes, Keith T Schmidt, Cody J Peer, et al.
Molecular Pharmacology
|
April 2, 2015
Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells
Elena V Fernandez, Kelie M Reece, Ariel M Ley, et al.
JNCI Cancer Spectrum
|
July 2, 2026
Sociodemographic trends in prostate cancer: Insights from the all of Us research program
Dhruv G Pillai, Vivian A Guedes, Nicholas G Micheletti, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 25, 2024
Revisiting the antiangiogenic mechanisms of fluorinated thalidomide derivatives
Johannes Sievers, Rabea Voget, Feiteng Lu, et al.
Scientific Reports
|
October 18, 2019
Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
Phoebe A Huang, Shaunna L Beedie, Cindy H Chau, et al.
Molecular Cancer Therapeutics
|
August 14, 2015
Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues
Shaunna L Beedie, Cody J Peer, Steven Pisle, et al.
Chemmedchem
|
July 7, 2026
Fluorinated Aminopiperidones as Non-Glutarimide Thalidomide Analogs: Stereodivergent Synthesis and Validation
Boštjan Adamlje, Tihomir Tomašič, Christian Steinebach, et al.
Clinical Genitourinary Cancer
|
May 21, 2013
Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity
William D Figg, Cindy H Chau, Ravi A Madan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2008
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer
Akinobu Hamada, Tristan Sissung, Douglas K Price, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 78) with videos related to
Sort By:
Page
of 8
Scientific Reports
|
May 25, 2021
Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p
Roberto H Barbier, Edel M McCrea, Kristi Y Lee, et al.
The Oncologist
|
August 1, 2021
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single-Dose Administration Under Fasting Conditions in Prostate Cancer
Lisa M Cordes, Keith T Schmidt, Cody J Peer, et al.
Molecular Pharmacology
|
April 2, 2015
Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells
Elena V Fernandez, Kelie M Reece, Ariel M Ley, et al.
JNCI Cancer Spectrum
|
July 2, 2026
Sociodemographic trends in prostate cancer: Insights from the all of Us research program
Dhruv G Pillai, Vivian A Guedes, Nicholas G Micheletti, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 25, 2024
Revisiting the antiangiogenic mechanisms of fluorinated thalidomide derivatives
Johannes Sievers, Rabea Voget, Feiteng Lu, et al.
Scientific Reports
|
October 18, 2019
Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
Phoebe A Huang, Shaunna L Beedie, Cindy H Chau, et al.
Molecular Cancer Therapeutics
|
August 14, 2015
Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues
Shaunna L Beedie, Cody J Peer, Steven Pisle, et al.
Chemmedchem
|
July 7, 2026
Fluorinated Aminopiperidones as Non-Glutarimide Thalidomide Analogs: Stereodivergent Synthesis and Validation
Boštjan Adamlje, Tihomir Tomašič, Christian Steinebach, et al.
Clinical Genitourinary Cancer
|
May 21, 2013
Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity
William D Figg, Cindy H Chau, Ravi A Madan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 4, 2008
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer
Akinobu Hamada, Tristan Sissung, Douglas K Price, et al.
Page
of 8